Our webinar for potential applicants of the Advancing Treatment Award is now available for you to watch!

The webinar provided information and tips on how to develop a successful application. We heard from Ang Armstrong, affected by MND, Jessica Lee, our Director of Research, Dr Richard Mead and Dr Jill Richardson, respectively Chair and Vice-Chair of the MN5DF Research Review Committee (RRC). They shared their perspectives and insights with the community.

Our Chair and Vice-Chair of the RRC discussed the critical aspects of validating therapeutic targets in MND research. They emphasised the importance of using robust and relevant models and the need for a clear demonstration of target engagement and pathway modulation. Ang Armstrong emphasised the need for accessible lay summaries to ensure that research proposals are understandable to those without a scientific background, which impacts funding decisions.

Our budget for the Advancing Treatments Award 2024 is £1.75 million, we invite researchers not to miss this opportunity and submit their applications before midday on the 17th of May.

Watch here.

More news & stories

View all
 picture
Fundraising MND stories
07 Nov 2026

Come together: Honouring Pat with music, community and fundraising at The Beatles Marathon

When Pat McGachan was diagnosed with motor neuron disease (MND) in 2021, his family knew they wanted to do something positive in the face of adversity. Inspired…
Read more
 picture
Fundraising
06 Nov 2026

IGNITE names My Name'5 Doddie Foundation as charity partner for the 2026 Nations Championship

IGNITE Experiences have appointed us as their official charity partner for the 2026 Nations Championship. IGNITE will be supporting us through fundraising activities…
Read more
 picture
Fundraising MND stories
03 Nov 2026

A wee wander in memory of Von

Brian Chalmers and his family took part in Dundee Kiltwalk's four-mile 'Wee Wander' to raise funds for us and honour Brian's mum, Yvonne (Von), who died from motor…
Read more
Bell icon

Join our Newsletter!

By subscribing, you confirm that you agree with our terms and conditions.